News
NNVC
1.350
+4.65%
0.060
Weekly Report: what happened at NNVC last week (0210-0214)?
Weekly Report · 1d ago
NanoViricides, Inc. Reports Financial Results for the Quarter Ended December 31, 2024
Press release · 3d ago
Weekly Report: what happened at NNVC last week (0203-0207)?
Weekly Report · 02/10 12:04
Biotech Alert: Searches spiking for these stocks today
TipRanks · 02/07 16:15
Weekly Report: what happened at NNVC last week (0127-0131)?
Weekly Report · 02/03 12:11
Weekly Report: what happened at NNVC last week (0120-0124)?
Weekly Report · 01/27 12:15
NanoViricides engages clinical research organization for NV-387 trial
TipRanks · 01/27 11:45
Weekly Report: what happened at NNVC last week (0113-0117)?
Weekly Report · 01/20 12:03
Weekly Report: what happened at NNVC last week (0106-0110)?
Weekly Report · 01/13 12:04
Weekly Report: what happened at NNVC last week (1230-0103)?
Weekly Report · 01/06 12:15
Weekly Report: what happened at NNVC last week (1223-1227)?
Weekly Report · 12/30/2024 12:07
Weekly Report: what happened at NNVC last week (1216-1220)?
Weekly Report · 12/23/2024 12:15
NanoViricides Claims NV-387 Could Be Key in Fighting Bird Flu Pandemic
Benzinga · 12/23/2024 11:38
Weekly Report: what happened at NNVC last week (1209-1213)?
Weekly Report · 12/16/2024 12:17
Weekly Report: what happened at NNVC last week (1202-1206)?
Weekly Report · 12/09/2024 12:15
Weekly Report: what happened at NNVC last week (1125-1129)?
Weekly Report · 12/02/2024 12:16
Weekly Report: what happened at NNVC last week (1118-1122)?
Weekly Report · 11/25/2024 12:04
Weekly Report: what happened at NNVC last week (1111-1115)?
Weekly Report · 11/18/2024 12:00
Weekly Report: what happened at NNVC last week (1104-1108)?
Weekly Report · 11/11/2024 12:19
Weekly Report: what happened at NNVC last week (1028-1101)?
Weekly Report · 11/04/2024 12:14
More
Webull provides a variety of real-time NNVC stock news. You can receive the latest news about Nanoviricides through multiple platforms. This information may help you make smarter investment decisions.
About NNVC
NanoViricides, Inc. is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. It is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.